LONDON – Cerenis Therapeutics SA is taking a huge bet on a Phase II trial of its recombinant high density lipoprotein (rHDL) product CER-001 in reducing cholesterol, announcing the start of a 500-patient U.S. and European study in patients with acute coronary syndrome. (BioWorld International) Read More
